CATX net incomeQ2 2026-$26.79M
CATX net income was -$26.79M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$21.48M a year earlier. For the full fiscal 2025 it was -$103.12M, compared with -$79.28M in fiscal 2024.
Perspective Therapeutics Inc. (CATX) financials
For the twelve months ended Jun 30, 2026, Perspective Therapeutics Inc. reported -$116.43M of net income.
- Net income, TTM
- -$116.43M
- Free cash flow, TTM
- -$121.19M
- EPS, diluted, TTM
- -$1.33
- Cash
- $48.49M
- Total debt
- $1.60M
- Market cap
- $96.1M
FY2016FY2023
FY2016FY2025
FY2016FY2025
CATX revenue and earnings growth
CATX EPSQ2 2026-$0.22
CATX diluted EPS was -$0.22 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.40, compared with -$1.23 in fiscal 2024.
CATX free cash flowQ2 2026-$34.84M
CATX free cash flow was -$34.84M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$20.98M a year earlier. For the full fiscal 2025 it was -$95.23M, compared with -$72.71M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $1.43M | $0 | $10.05M | $9.68M | $7.31M | $5.92M | $4.76M | $4.77M |
| Cost of revenue | - | - | - | - | $4.93M | $4.56M | $4.27M | $4.08M | $3.92M | $4.64M |
| Gross profit | - | - | $1.43M | $0 | $5.12M | $5.12M | $3.05M | $1.84M | $838.0K | $129.0K |
| Research and development | $84.22M | $41.64M | $21.31M | $881.0K | $1.43M | $1.13M | $1.47M | $1.75M | $965.0K | $528.0K |
| Selling, general and admin | $30.23M | $26.61M | $21.06M | $7.49M | $4.69M | $4.57M | $4.17M | $4.17M | $3.92M | $3.79M |
| Operating income | -$113.56M | -$90.89M | -$40.94M | -$8.67M | -$3.45M | -$3.48M | -$5.25M | -$6.73M | -$6.31M | -$5.08M |
| Interest expense | - | - | $84.0K | $0 | - | - | - | - | $0 | $1.0K |
| Pre-tax income | -$104.43M | -$80.43M | -$40.11M | -$8.05M | - | - | - | - | - | - |
| Income tax | -$793.0K | -$2.10M | -$2.65M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$103.12M | -$79.28M | -$46.51M | -$10.76M | -$3.39M | -$3.45M | -$5.14M | -$6.70M | -$6.16M | -$4.71M |
| EPS, basic | -$1.40 | -$1.23 | -$1.74 | -$0.08 | -$0.03 | -$0.05 | -$0.08 | -$0.12 | -$0.11 | -$0.09 |
| EPS, diluted | -$1.40 | -$1.23 | -$1.74 | - | -$0.03 | -$0.05 | -$0.08 | -$0.12 | -$0.11 | -$0.09 |
| Diluted shares | 73.8M | 64.4M | 26.8M | - | 103.8M | 67.6M | 67.0M | 55.2M | 55.0M | 55.0M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.63M | $61.58M | $9.24M | $20.99M | $63.83M | $2.39M | $5.33M | $2.60M | $6.11M | $10.32M |
| Short-term investments | $114.11M | $165.34M | $0 | $22.76M | $0 | - | - | $825.0K | $3.04M | $2.25M |
| Receivables | $6.0K | $116.0K | $1.17M | $1.36M | $2.01M | $2.04M | $1.15M | $1.19M | $726.0K | $605.0K |
| Inventory | - | - | - | $1.41M | $980.0K | $645.0K | $530.0K | $494.0K | $323.0K | $334.0K |
| Current assets | $148.39M | $231.16M | $16.84M | $53.22M | $67.30M | $5.51M | $7.32M | $5.45M | $10.29M | $13.63M |
| Goodwill | - | $0 | $24.06M | $0 | - | - | - | - | - | - |
| Total assets | $266.97M | $341.10M | $97.89M | $58.09M | $70.42M | $8.70M | $9.42M | $7.46M | $12.27M | $18.10M |
| Current liabilities | $28.68M | $18.23M | $15.66M | $3.12M | $1.80M | $1.57M | $1.12M | $1.83M | $1.11M | $1.09M |
| Total debt | $1.63M | $1.68M | $1.73M | $0 | - | - | - | - | - | - |
| Total liabilities | $59.94M | $50.43M | $22.71M | $3.45M | $3.01M | $2.98M | $1.74M | $2.42M | $1.67M | $1.70M |
| Shareholders' equity | $207.03M | $290.67M | $75.18M | $54.64M | $67.41M | $5.72M | $7.68M | $5.03M | $10.60M | $16.40M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$82.48M | -$18.29M | -$36.91M | -$10.40M | -$2.84M | -$3.64M | -$5.05M | -$5.71M | -$5.71M | -$3.88M |
| Capital expenditures | $12.75M | $54.41M | $1.07M | $282.0K | $381.0K | $273.0K | $444.0K | $337.0K | $549.0K | $479.0K |
| Free cash flow | -$95.23M | -$72.71M | -$37.98M | -$10.68M | -$3.22M | -$3.91M | -$5.49M | -$6.05M | -$6.26M | -$4.36M |
| Investing cash flow | $41.23M | -$218.93M | $24.37M | -$28.99M | -$410.0K | -$287.0K | $401.0K | $1.86M | $1.51M | $8.76M |
| Financing cash flow | $10.30M | $289.38M | $785.0K | $28.0K | $64.68M | $994.0K | $7.37M | $521.0K | -$9.0K | $39.0K |
| Stock-based compensation | $8.97M | $5.39M | $3.74M | $983.0K | $386.0K | $495.0K | $420.0K | $404.0K | $372.0K | $290.0K |
| Depreciation and amortization | $3.25M | $2.31M | $986.0K | - | - | - | - | - | $68.0K | $471.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2021 | Jun 30, 2020 | Jun 30, 2019 | Jun 30, 2018 | Jun 30, 2017 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -100.0% | 3.9% | 32.3% | 23.5% | 24.4% | -0.2% | - |
| Gross margin | - | - | 100.0% | - | 50.9% | 52.9% | 41.7% | 31.1% | 17.6% | 2.7% |
| Operating margin | - | - | -2855.0% | - | -34.3% | -35.9% | -71.8% | -113.6% | -132.5% | -106.6% |
| Net margin | - | - | -3243.2% | - | -33.7% | -35.6% | -70.3% | -113.1% | -129.4% | -98.8% |
| Free cash flow margin | - | - | -2648.9% | - | -32.0% | -40.4% | -75.1% | -102.1% | -131.5% | -91.5% |
| Return on equity | -49.8% | -27.3% | -61.9% | -19.7% | -5.0% | -60.2% | -67.0% | -133.2% | -58.1% | -28.7% |
| Return on assets | -38.6% | -23.2% | -47.5% | -18.5% | -4.8% | -39.6% | -54.6% | -89.9% | -50.2% | -26.0% |
| Current ratio | 5.17 | 12.68 | 1.07 | 17.07 | 37.37 | 3.50 | 6.53 | 2.97 | 9.30 | 12.46 |
| Debt to equity | 0.01 | 0.01 | 0.02 | 0.00 | - | - | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $2.19M |
| Cost of revenue | - | - | - | - | - | - | - | - | - | - | - | $1.45M |
| Gross profit | - | - | - | - | - | - | - | - | - | - | -$39.0K | $738.0K |
| Research and development | $21.54M | $21.37M | $32.92M | $20.34M | $16.62M | $14.33M | $12.88M | $12.03M | $9.28M | $7.45M | $7.08M | $5.55M |
| Selling, general and admin | $7.79M | $6.99M | $6.95M | $7.73M | $7.71M | $7.84M | $8.25M | $6.97M | $5.51M | $5.88M | $4.94M | $4.47M |
| Operating income | -$29.26M | -$28.28M | -$39.83M | -$27.86M | -$24.04M | -$21.83M | -$44.98M | -$18.63M | -$14.26M | -$13.01M | -$11.68M | -$9.75M |
| Interest expense | - | - | - | - | - | - | - | - | - | - | $24.0K | $14.0K |
| Pre-tax income | -$26.98M | -$26.19M | -$38.28M | -$25.97M | -$22.00M | -$18.18M | -$42.27M | -$15.12M | -$11.21M | -$11.82M | -$11.64M | -$9.57M |
| Income tax | - | - | - | - | - | - | - | - | - | - | $7.85M | $0 |
| Net income | -$26.79M | -$26.19M | -$37.49M | -$25.97M | -$21.48M | -$18.18M | -$40.17M | -$15.12M | -$11.70M | -$12.28M | -$24.68M | -$10.36M |
| EPS, basic | -$0.22 | -$0.25 | -$0.51 | -$0.35 | -$0.29 | -$0.25 | - | -$0.21 | -$0.18 | -$0.25 | - | -$0.37 |
| EPS, diluted | -$0.22 | -$0.25 | -$0.51 | -$0.35 | -$0.29 | -$0.25 | - | -$0.21 | -$0.18 | -$0.25 | - | -$0.37 |
| Diluted shares | 120.7M | 103.6M | - | 74.3M | 74.2M | 72.4M | - | 70.6M | 66.6M | 49.5M | - | 28.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $48.49M | $53.97M | $30.63M | $26.76M | $28.85M | $44.41M | $61.58M | $226.44M | $252.00M | $142.12M | $9.24M | $17.98M |
| Short-term investments | $188.39M | $216.96M | $114.11M | $147.38M | $162.73M | $167.30M | $165.34M | $41.40M | $40.87M | $38.53M | $0 | $0 |
| Receivables | $269.0K | $58.0K | $6.0K | $179.0K | $225.0K | $78.0K | $116.0K | $217.0K | $142.0K | $999.0K | $1.17M | $1.73M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | $1.01M |
| Current assets | $241.52M | $275.35M | $148.39M | $178.50M | $195.96M | $215.74M | $231.16M | $270.17M | $294.24M | $188.20M | $16.84M | $21.69M |
| Goodwill | - | - | - | - | - | - | $0 | $24.06M | $24.06M | $24.06M | $24.06M | $27.32M |
| Total assets | $392.02M | $410.77M | $266.97M | $294.82M | $310.73M | $329.35M | $341.10M | $391.15M | $385.92M | $278.29M | $97.89M | $110.52M |
| Current liabilities | $36.54M | $31.49M | $28.68M | $20.62M | $12.99M | $12.68M | $18.23M | $28.14M | $10.61M | $14.50M | $15.66M | $8.12M |
| Total debt | $1.60M | $1.61M | $1.63M | $1.64M | $1.65M | $1.66M | $1.68M | $1.69M | $1.71M | $1.71M | $1.73M | $1.74M |
| Total liabilities | $68.16M | $63.33M | $59.94M | $52.61M | $45.03M | $44.70M | $50.43M | $62.68M | $44.92M | $48.40M | $22.71M | $11.75M |
| Shareholders' equity | $323.86M | $347.44M | $207.03M | $242.22M | $265.69M | $284.64M | $290.67M | $328.47M | $341.00M | $229.89M | $75.18M | $98.77M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.65M | -$31.47M | -$24.66M | -$16.29M | -$19.95M | -$21.58M | -$26.61M | $3.37M | -$8.90M | $13.85M | -$9.01M | -$10.11M |
| Capital expenditures | $14.20M | $6.86M | $5.08M | $1.99M | $1.03M | $4.66M | $14.61M | $29.71M | $1.01M | $9.07M | $89.0K | $227.0K |
| Free cash flow | -$34.84M | -$38.33M | -$29.73M | -$18.28M | -$20.98M | -$26.24M | -$41.22M | -$26.35M | -$9.92M | $4.78M | -$9.10M | -$10.34M |
| Investing cash flow | $15.02M | -$109.55M | $28.54M | $13.99M | $4.26M | -$5.57M | -$138.60M | -$29.74M | -$3.29M | -$47.30M | -$89.0K | -$227.0K |
| Financing cash flow | $147.0K | $164.36M | -$13.0K | $213.0K | $132.0K | $9.97M | $345.0K | $628.0K | $122.08M | $166.33M | $352.0K | $1.0K |
| Stock-based compensation | $3.05M | $2.55M | $2.31M | $2.16M | $2.40M | $2.10M | $2.06M | $1.95M | $719.0K | $656.0K | $720.0K | $451.0K |
| Depreciation and amortization | $1.14M | $1.13M | $1.01M | $775.0K | $733.0K | $732.0K | $709.0K | $669.0K | $572.0K | $356.0K | $302.0K | $259.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | - | - | 27.3% |
| Gross margin | - | - | - | - | - | - | - | - | - | - | - | 33.8% |
| Operating margin | - | - | - | - | - | - | - | - | - | - | - | -446.2% |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | -474.0% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - | - | -473.1% |
| Current ratio | 6.61 | 8.75 | 5.17 | 8.66 | 15.09 | 17.02 | 12.68 | 9.60 | 27.73 | 12.98 | 1.07 | 2.67 |
| Debt to equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
Source: XBRL data Perspective Therapeutics Inc. files with the SEC, latest filing dated Aug 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CATX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CATX | - | - | -$116.43M | - | $96.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
CATX FAQ
6 questionsIs CATX profitable?
No. Perspective Therapeutics Inc. reported a net loss of $116.43M for the twelve months ended Jun 30, 2026.How much cash and debt does CATX have?
Perspective Therapeutics Inc. reported $48.49M in cash and cash equivalents and $1.60M of debt on its most recent balance sheet in SEC filings.What is CATX free cash flow?
Perspective Therapeutics Inc. generated -$121.19M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$93.07M less capital expenditures.What is CATX earnings per share?
Diluted earnings per share were -$1.33 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did CATX last report financial results?
The latest statements here come from Perspective Therapeutics Inc.'s 10-Q filed on Aug 10, 2026, covering the period ended Jun 30, 2026.Where does this CATX financial data come from?
Quantisnow builds these statements from the structured XBRL data Perspective Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.